esomeprazole/ASA Fixed Dose Combination (FDC)

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Effect of Food

Conditions

Effect of Food, Pharmacokinetics

Trial Timeline

Jun 1, 2010 → Sep 1, 2010

About esomeprazole/ASA Fixed Dose Combination (FDC)

esomeprazole/ASA Fixed Dose Combination (FDC) is a phase 1 stage product being developed by AstraZeneca for Effect of Food. The current trial status is completed. This product is registered under clinical trial identifier NCT01163630. Target conditions include Effect of Food, Pharmacokinetics.

What happened to similar drugs?

2 of 4 similar drugs in Effect of Food were approved

Approved (2) Terminated (0) Active (2)
🔄GP404141 + NplateGEROPHARMPhase 3
Budesonide NasalJohnson & JohnsonApproved
🔄daptomycinMerckPhase 3
Moxifloxacin 400 mgBayerApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01163630Phase 1Completed

Competing Products

20 competing products in Effect of Food

See all competitors